All In Biotech

Drug Trial Radar · NCT04049097

Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial

An Open-label, Non-randomized Trial to Investigate the Efficacy and Safety of Early Versus Delayed Start of Arimoclomol in Patients With Sporadic Inclusion Body Myositis Who Have Completed the IBM4809 Trial

Last checked: Nov 19, 2026Latest source record: Sep 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

121

Actual

Start

May 20, 2019

Primary completion

Nov 15, 2021

Study completion Nov 15, 2021

Sponsor

Lead sponsor
ZevraDenmarkIndustry
Sponsor type
Industry
Collaborators
University of Kansas Medical Center; University College, London
First posted
Aug 7, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multicenter, nonrandomized, open-label, uncontrolled clinical extension trial designed to compare the efficacy and safety of early versus delayed start of arimoclomol in the treatment of Inclusion Body Myositis (IBM)

Conditions

  • Inclusion Body Myositis

Interventions

  • ArimoclomolDrug

    2 capsules (2 x 124 mg arimoclomol base; equivalent to 2 x 200 mg arimoclomol citrate) taken 3 times daily during breakfast, early afternoon, and at bedtime

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Inclusion Body Myositis Functional Rating Scale (IBMFRS) Total ScoreTime frame: Change from Baseline in IBM-OLE to Early Termination Visit (variable, an average of approximately 28 weeks).

Locations

12 sites in 2 countries. Site status is shown where the registry gives one.

  • Phoenix Neurological Associates

    Phoenix, Arizona

  • University of California

    Irvine, California

  • University of Colorado School of Medicine

    Aurora, Colorado

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Johns Hopkins University

    Baltimore, Maryland

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • University of Rochester

    Rochester, New York

  • The Ohio State University

    Columbus, Ohio

  • Nerve and Muscle Center of Texas

    Houston, Texas

  • University of Utah

    Salt Lake City, Utah

  • University of Virginia

    Charlottesville, Virginia

  • University College of London

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.